Covered recipient · General Payments record
TRUDY HALL
General Payments · PY2018–2024
$821.36
- Reported across 14 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $708.78 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $216.73 | 5 |
| Bayer HealthCare Pharmaceuticals Inc. | $125.01 | 1 |
| GlaxoSmithKline, LLC. | $116.39 | 1 |
| PROGENICS PHARMACEUTICALS, INC. | $100.90 | 1 |
| ViiV Healthcare Company | $90.41 | 1 |
| Genentech USA, Inc. | $59.34 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $125.01 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086241918 | CMS |
| Genentech USA, Inc. | $59.34 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133127593 | CMS |
| GlaxoSmithKline, LLC. | $116.39 | 05/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116309171 | CMS |
| Novo Nordisk Inc | $55.10 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108576827 | CMS |
| Novo Nordisk Inc | $41.85 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108574876 | CMS |
| Novo Nordisk Inc | $41.85 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108578005 | CMS |
| Novo Nordisk Inc | $55.10 | 07/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108574612 | CMS |
| Novo Nordisk Inc | $22.83 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108577249 | CMS |
| PROGENICS PHARMACEUTICALS, INC. | $100.90 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128504746 | CMS |
| ViiV Healthcare Company | $90.41 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112748028 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.